The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Thieme Country of Publication: Germany NLM ID: 0177722 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1439-4286 (Electronic) Linking ISSN: 00185043 NLM ISO Abbreviation: Horm Metab Res Subsets: MEDLINE
    • Publication Information:
      Original Publication: Stuttgart, Thieme.
    • Subject Terms:
      Anti-Obesity Agents*/adverse effects ; Anti-Obesity Agents*/therapeutic use ; Exenatide*/adverse effects ; Exenatide*/therapeutic use ; Glucagon-Like Peptide-1 Receptor*/agonists ; Glucagon-Like Peptides*/adverse effects ; Glucagon-Like Peptides*/therapeutic use ; Hypoglycemic Agents*/adverse effects ; Hypoglycemic Agents*/therapeutic use ; Liraglutide*/adverse effects ; Liraglutide*/therapeutic use ; Obesity*/drug therapy; Humans ; Weight Loss
    • Abstract:
      Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes. The random-effect model was used to pool data extracted from included literatures. The weighted mean difference (WMD), odds ratio and 95% confidence interval (CI) were used to present the meta-analysis results (PROSPERO registration number: CRD 42020173199). The sources of intertrial heterogeneity, bias and the robustness of results were evaluated by subgroup analysis, sensitivity analysis and regression analysis, respectively. A total of 24 RCTs were recruited in the present analysis which included 5867 patients. The results showed that the treatment of overweight/obese patients without diabetes with GLP-1RAs including liraglutide, exenatide and semaglutide significantly achieved greater weight loss than placebo [WMD=-5.39, 95% CI (-6.82, -3.96)] and metformin [WMD=-5.46, 95% CI (-5.87, -5.05)]. The subgroup analysis showed that semaglutide displayed the most obvious antiobesity effect in terms of weight loss, the reduction of body mass index (BMI) and waist circumference (WC). However, GLP-1RAs treatments had more gastrointestinal adverse events (such as nausea and vomiting) than placebo and Met. The subgroup analysis also represented that semaglutide displayed the lowest risk of gastrointestinal adverse events among three kinds of GLP-1RAs. Our meta-analysis demonstrated that GLP-1RA had a superior antiobesity effect than placebo/Met in overweight/obese patients without diabetes in terms of body weight, BMI, and WC, especially for semaglutide, which had more obvious antiobesity effect and lower GI adverse events than liraglutide and exenatide.
      Competing Interests: The authors declare that they have no conflict of interest.
      (Thieme. All rights reserved.)
    • Accession Number:
      0 (Anti-Obesity Agents)
      0 (Glucagon-Like Peptide-1 Receptor)
      0 (Hypoglycemic Agents)
      53AXN4NNHX (semaglutide)
      62340-29-8 (Glucagon-Like Peptides)
      839I73S42A (Liraglutide)
      9P1872D4OL (Exenatide)
    • Publication Date:
      Date Created: 20220505 Date Completed: 20220718 Latest Revision: 20220804
    • Publication Date:
      20240104
    • Accession Number:
      10.1055/a-1844-1176
    • Accession Number:
      35512849